Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of the National Cancer Institute
|
May 4, 1988
Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells
R A Beckman, P J McFall, B I Sikic, et al.
The Journal of Biological Chemistry
|
October 10, 1981
On the fidelity of DNA replication. Effect of the next nucleotide on proofreading
T A Kunkel, R M Schaaper, R A Beckman, et al.
The Journal of Biological Chemistry
|
April 25, 1981
On the fidelity of DNA replication. Nucleoside monophosphate generation during polymerization
L A Loeb, D K Dube, R A Beckman, et al.
Cancer Chemotherapy and Pharmacology
|
October 6, 2000
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan
S Akhtar, R A Beckman, D R Mould, et al.
British Journal of Cancer
|
April 20, 2001
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
M Gore, G Rustin, J Schüller, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
January 1, 1979
On the fidelity of DNA replication
L A Loeb, L A Weymouth, T A Kunkel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
M Gore, A Oza, G Rustin, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
M R Trusheim, A A Shrier, Z Antonijevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
D L Clarke-Pearson, L Van Le, T Iveson, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of the National Cancer Institute
|
May 4, 1988
Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells
R A Beckman, P J McFall, B I Sikic, et al.
The Journal of Biological Chemistry
|
October 10, 1981
On the fidelity of DNA replication. Effect of the next nucleotide on proofreading
T A Kunkel, R M Schaaper, R A Beckman, et al.
The Journal of Biological Chemistry
|
April 25, 1981
On the fidelity of DNA replication. Nucleoside monophosphate generation during polymerization
L A Loeb, D K Dube, R A Beckman, et al.
Cancer Chemotherapy and Pharmacology
|
October 6, 2000
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan
S Akhtar, R A Beckman, D R Mould, et al.
British Journal of Cancer
|
April 20, 2001
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
M Gore, G Rustin, J Schüller, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
January 1, 1979
On the fidelity of DNA replication
L A Loeb, L A Weymouth, T A Kunkel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
M Gore, A Oza, G Rustin, et al.
Clinical Pharmacology and Therapeutics
|
September 20, 2016
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
M R Trusheim, A A Shrier, Z Antonijevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
D L Clarke-Pearson, L Van Le, T Iveson, et al.
Page
of 2